As a common disease in the clinical cardiovascular field, arrhythmia seriously affects people’s daily work and life. Although medical scientists have been working on anti-arrhythmic drug research for a long time, unfortunately, no obvious breakthrough has been achieved. It is divided into tachyarrhythmia mainly with increased heart rate and bradyarrhythmia mainly with slow heart rate, but there are also cases of sinus bradycardia with premature ventricular contractions and premature ventricular contractions with cardiac insufficiency, etc. Complex arrhythmia has become a very difficult clinical problem.
Traditional Chinese medicine has a rich understanding of arrhythmia, which is classified as “palpitations” and “heart palpitations” according to clinical symptoms. “category. Traditional Chinese medicine advocates the treatment strategy of “adjusting to leveling”. Through the action of drugs, the body’s own ability to heal is mobilized, so that the fast heart rate can be lowered and the slow heart rate can be adjusted to restore the normal state of the heart rate.
Under the theory of collateral diseases in TCM, the researchers of Yiling Pharmaceutical Co., Ltd. proposed a change of thinking from “anti-rhythm” to “regulatory rhythm”. The direction of the heart rhythm is switched. It is put forward that deficiency of both qi and yin is the foundation, the vanity of the collaterals is the basic pathological link, and the blood stasis of the collaterals is an important influencing factor. Referring to the experience of the Qing Dynasty physician Ye Tianshi in the treatment of cardiac arrhythmia, according to the pathogenesis and clinical manifestations of arrhythmia, the treatment method of “replenishing qi and nourishing yin, promoting blood circulation and dredging collaterals, clearing the heart and soothing the nerves” was determined. The prescription of Shensong Yangxin Capsule was developed by the medication rule of “Wenqing Butong”.
Experimental studies have shown that Shensong Yangxin Capsule has the effect of regulating multi-ion channel block and non-ion channel, regulating cardiac autonomic nerve, treating various tachyarrhythmias, and at the same time it can improve cardiac conduction Therefore, it can also treat bradyarrhythmias, and at the same time, it can also eliminate the symptoms of insomnia, palpitation, shortness of breath, and fatigue caused by various arrhythmias.
In addition, Shensong Yangxin Capsule has also carried out a number of randomized, double-blind, multi-center clinical evidence-based studies focusing on the treatment of various types of arrhythmias:
Shensong Yangxin A clinical study of 1476 cases of arrhythmia with capsules has confirmed that Shensongyangxin capsules are better than mexiletine in the treatment of premature ventricular contractions, better than propafenone in the treatment of paroxysmal atrial fibrillation, and can also improve the ventricular rate of patients with bradyarrhythmias.
The clinical study of Shensong Yangxin Capsule in the treatment of 333 cases of sinus bradycardia with premature ventricular contractions has confirmed that it can effectively reduce the number of premature ventricular contractions, increase the ventricular rate, and fill the gap of treating both speed and slowness and integrating rhythm regulation. Drug treatment blank.
The clinical study of Shensong Yangxin Capsule in the treatment of 465 cases of heart failure with premature ventricular contraction confirmed that Shensong Yangxin Capsule can effectively reduce premature ventricular contraction and improve cardiac function, providing a safe and effective treatment for such patients. medicine.
Unique theoretical formula and exact clinical research results, “Shensong Yangxin Capsule in the treatment of arrhythmia application research” won the second prize of National Science and Technology Progress Award in 2009, Shensong Yangxin Capsule in the treatment of sinus palsy The research on premature ventricular and heart failure with ventricular premature also won the first prize of the National Science and Technology Progress Award in 2019. Based on solid evidence and good curative effect, Shensong Yangxin Capsule has been listed in the National Health Commission’s “Guidelines for Rational Drug Use for Arrhythmia” and the “13th Five-Year Plan” textbook for arrhythmia drugs in Western Medicine “Internal Medicine”, as well as the Chinese Medical Association. “Guidelines for Rational Drug Use for Arrhythmias”, “Chinese Expert Consensus on Ventricular Arrhythmias” (2016, 2020), “Atrial Fibrillation: Current Understanding and Treatment Recommendations” (2015, 2018, 2021), “Ventricular Arrhythmia” Arrhythmia Chinese Expert Consensus Basic Edition (2021) and other guideline consensuses, it is widely used in clinical practice.
With the deepening of research on arrhythmia, the medical community has realized that arrhythmia is a refractory disease with complex pathogenesis and various types of lesions. “It cannot solve the complex problems that cause a variety of arrhythmias, and it is necessary to shift from “anti-rhythm” to “rhythm regulation” in order to effectively treat arrhythmia.